Medical Condition News

RSS

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.

9 Jun 2010

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Northwest Biotherapeutics, Inc., developer of the DCVax personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr. Navid Malik of the London-based Matrix Group.

9 Jun 2010

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Chelsea Therapeutics International, Ltd. announced that during a teleconference yesterday, the U.S. Food and Drug Administration requested that the company delay the initiation of its proposed Phase II clinical study of CH-4051 in rheumatoid arthritis and indicated that the agency is requesting additional detail from the preclinical studies previously submitted as part of the company's investigational new drug application.

9 Jun 2010

Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma.

9 Jun 2010

Additional markers of risk for diabetic microvascular complications beyond Hemoglobin A1c needed

The "gold standard" diabetes test, Hemoglobin A1c (A1C), explains much less about the risk of cardiovascular complications in patients with diabetes than originally thought, according to an article in the June 9 issue of the Journal of the American Medical Association (JAMA). The article entitled, "Beyond HbA1c: Need for Additional Markers of Risk for Diabetic Microvascular Complications," was co-authored by Irl Hirsch, M.D., of the University of Washington Medical School (Seattle, WA) and Michael Brownlee, M.D., of the Albert Einstein College of Medicine.

9 Jun 2010

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).

9 Jun 2010

Patients with BAI can be managed non-operatively with beta-blockade: Researchers

Select patients with blunt aortic injury can be safely managed non-operatively with beta-blockade to lower the heart rate and blood pressure, according to a new study from the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery.

9 Jun 2010

Biofeedback training on MPA decreases performance anxiety, improves performance in musicians

Traditionally, the most successful methods used to combat stage fright have been prescribed medications (beta blockers) and aerobic exercise. In the most recent issue of Biofeedback, researchers studied another technique: the effect of biofeedback training on Musical Performance Anxiety (MPA). MPA is a severe form of stage fright marked by high anxiety levels and impaired performance.

9 Jun 2010

Research shows excessive daytime sleepiness increases depression symptoms among high school seniors

High school seniors with excessive daytime sleepiness have an elevated risk for depression, suggests a research abstract that will be presented Wednesday, June 9, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

9 Jun 2010

Screen time contributes to headache, backache in school-aged teenagers

The amount of time teenagers spend in front of TV screens and monitors has been associated with physical complaints. A large study of more than 30,000 Nordic teenagers published in the open access journal BMC Public Health has shown that TV viewing, computer use and computer gaming (screen time) were consistently associated with back pain and recurrent headaches.

9 Jun 2010

Pecans may delay progression of age-related motor neuron degeneration: Study

Eating about a handful of pecans each day may play a role in protecting the nervous system, according to a new animal study published in the current issue of Current Topics in Nutraceutical Research. The study, conducted at the Center for Cellular Neurobiology at the University of Massachusetts Lowell, suggests adding pecans to your diet may delay the progression of age-related motor neuron degeneration. This may include diseases like amyotropic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

9 Jun 2010

Self-reported relationship satisfaction among new parents associated with objective total sleep time

First-time parents' relationship satisfaction is related to the amount of sleep they get while caring for an infant, according to a research abstract that will be presented Wednesday, June 9, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

9 Jun 2010

Highly variable sleep schedules predict elevated suicide risk

Highly variable sleep schedules predict an elevated risk for suicide independent of depression in actively suicidal young adults, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

9 Jun 2010

Promising technique to curb devastating effects of strokes

A clot vacuum cleaner that sucks out stroke-producing blockages from blood vessels in the brain sounds like science fiction. But 27 Calgary patients who were rescued from massive strokes know the endovascular procedure is for real, Dr. Mayank Goyal told the Canadian Stroke Congress today.

9 Jun 2010

Two variants of LPA gene associated with increased risk of coronary heart disease

Celera Corporation and its collaborators at the University of California at San Francisco today announced the publication of a paper confirming the association of an increased risk of coronary heart disease (CHD) and two variants of the LPA gene. The two LPA single nucleotide polymorphisms (SNPs) are Ile4399Met, a polymorphism in the protease-like domain of LPA, and rs10455872, a SNP located in a non-coding region of the LPA gene.

9 Jun 2010

Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure

Vital Therapies, Inc., (VTI) is pleased to announce that the first two subjects have been enrolled at King's College Hospital in London in the expansion of its SILVER (Stabilization In LiVER failure) clinical trial in Europe. The trial is evaluating whether VTI's biological cellular therapy product, ELAD®, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure (ACLF).

9 Jun 2010

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

The Cancer Research Institute, a nonprofit organization dedicated to the development of immune system-based treatments for cancer, announced today its celebration of a significant new breakthrough in the treatment of melanoma, the deadliest form of skin cancer. The new treatment, a cancer immunotherapy created by Cancer Research Institute Scientific Advisory Council Associate Director James P. Allison, Ph.D., is designed to "take the brakes off the immune system," and is the first treatment ever proven to extend life for patients whose melanomas are unresponsive to existing cancer therapies.

9 Jun 2010

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.

9 Jun 2010

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.

9 Jun 2010

Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced Phase 1 data for its novel heart failure Positron Emission Tomography (PET) imaging agent, LMI 1195, which is in development for the evaluation of patients at risk of heart failure or sudden cardiac death.

9 Jun 2010

Medical Condition News

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

Additional markers of risk for diabetic microvascular complications beyond Hemoglobin A1c needed

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Patients with BAI can be managed non-operatively with beta-blockade: Researchers

Biofeedback training on MPA decreases performance anxiety, improves performance in musicians

Research shows excessive daytime sleepiness increases depression symptoms among high school seniors

Screen time contributes to headache, backache in school-aged teenagers

Pecans may delay progression of age-related motor neuron degeneration: Study

Self-reported relationship satisfaction among new parents associated with objective total sleep time

Highly variable sleep schedules predict elevated suicide risk

Promising technique to curb devastating effects of strokes

Two variants of LPA gene associated with increased risk of coronary heart disease

Vital Therapies commences enrollment in ELAD SILVER trial for acute-on-chronic liver failure

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Lantheus Medical Imaging reports Phase 1 data of LMI 1195 heart failure PET imaging agent

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News